

Certificate of Analysis

PI 3-Kinase (p110δ/p85α) mouse

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-789, 14-789-K, 14-789M

Parent Lot # 1604633

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: Complex of *N*-terminal 6His-tagged recombinant mouse p110delta full length and untagged, recombinant, mouse p85alpha full length. Co-expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA-agarose.

Purity (p110δ and p85α combined) 76% by SDS-PAGE and Coomassie blue staining. p110δ MW = 124kDa, p85α MW = 84kDa.

Specific Activity (Parent lot# 1604633): 343U/mg, where one unit of PI 3-Kinase (p110δ/p85α) activity is defined as 1nmol phosphatidylinositol 3,4,5-trisphosphate (PIP3) formed per minute at room temperature with a final ATP concentration of 100μM.

Formulation: 0.774mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 0.2mM PMSF, 1mM benzamidine, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 0.0–1.6ng of this enzyme phosphorylated 10μM phosphatidylinositol 4, 5-bisphosphate in the assay referenced on page two.



MS Tryptic Fingerprint: Confirmed product identity as PI 3-Kinase (p110δ/p85α) with the p110δ and p85α translated sequences listed on pages three and five.



Certificate of Analysis

Eurofins PI3 Kinase Homogeneous Time-resolved Fluorescence (HTRF) Class I Reagent Kits

The following Eurofins kits are suitable for use with this enzyme:

Cat. No	Kit Description
33-016	PI3 Kinase 4-Step Assay Reagent 1-Plate Kit
33-017	PI3 Kinase 4-Step Assay Reagent 5-Plate Kit
33-036	PI3 Kinase 4-Step Assay Reagent Kit (10000 wells)
33-037	PI3 Kinase 4-Step Assay Reagent Kit (50000 wells)
33-040	PI3 Kinase 3-Step Assay Reagent Kit (384 wells)
33-041	PI3 Kinase 3-Step Assay Reagent Kit (1920 wells)
33-047	PI3 Kinase 3-Step Assay Reagent Kit (10000 wells)

Kits 33-016, 33-017, 33-036 and 33-037 provide reagents and assay details for the Eurofins standard 4-step HTRF assay. This assay format is suitable for the majority of small and medium throughput screening work. The 3-step HTRF assay (kits 33-040, 33-041, 33-047) was introduced to reduce the number of assay steps to aid high throughput screening. Items 33-040 and 33-041 are intended as introductory kits for 3-step procedure work up. Please contact us for any further information regarding different kit formats (discoveryservices@eurofins.com).

Certificate of Analysis

p110δ Sequence Information

<u>Protein</u>	Mouse p110δ
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	M37 of the recombinant sequence is equivalent to M1 of mouse p110δ
<u>Accession number</u>	GenBank NM_008840

Recombinant p110δ amino acid sequence:

```

1 MSYYHHHHH DYDIPTTENL YFQGAMDPEF KGLRRQMPPG VDCPMEFWTK EESQSVVDF
61 LLPTGVYLN FVSRNANLST IKQVLWHRAQ YEPLFHMLSD PEAYVFTCVN QTAEQQELED
121 EQRRLCDIQP FLPVLRRLVAR EGDRVKKLIN SQISLLIGKG LHEFDSL RDP EVNDFRTKMR
181 QFCEEAHAHR QQLGWVEWLQ YSFPLQLEPS ARGWRAGLLR VSNRALLVNV KFEGSEESFT
241 FQVSTKDMPL ALMACALRKK ATVFRQPLVE QPEEYALQVN GRHEYLYGNY PLCHFQYICS
301 CLHSGLTPHL TMVHSSSILA MRDEQSNPAP QVQKPRAKPP PIPAKKPSSV SLWSLEQPFS
361 IELIEGRKVN ADERMKLVVQ AGLFHGNEML CKTVSSSEVN VCSEPVWKQR LEFDISVCDL
421 PRMARLCFAL YAVVEKAKKA RSTKKKSKKA DCPIAWANLM LFDYKDQLKT GERCLYMWPS
481 VPDEKCELLN PAGTVRGNPN TESAAALVIY LPEVAPHPVY FPALEKILEL GRHGERGRIT
541 EEEQLQLREI LERRSGGELY EHEKDLVWKM RHEVQEHFPE ALARLLLVT K WNKHEDVAQM
601 LYLLCSWPEL PVLSALELLD FSPDCYVGS FAIKSLRKL T DDEL FQYLLQ LVQVLKYESY
661 LDCELT KFL GRALANRKIG HFLFWHLRSE MHVPSVALRF GLIMEAYCRG STHHMKVLMK
721 QGEALS K LKA LND FVKVSSQ KTTKPQTKEM MHMCMRQETY MEALSHLQSP LDPSTLLEE V
781 CVEQCT F MDS KMKPLWIMYS SEEAGSAGNV GIIFKNGDDL RQDMLTLQMI QLM DVLWKQE
841 GLDLRMPY G CLPTGDR TGL IEVVLHSDTI ANIQLNKS NM AATAAFNKDA LLNWLKSKNP
901 GEALDRAIE E FTLS CAGYCV ATYVLGIGDR HSDNIMIRES GQLFHIDFGH FLGNFKTKFG
961 INRERVPFIL TYDFVHVIQQ GKTNNSEKFE RFRGYCERAY TILRRHGLLF LHLFALMRAA
1021 GLPELSCSKD IQYLKDSLAL GKTEEEALKH FRVKFNEALR ESWKTKVNW L AHNVS KDN RQ
  
```

Recombinant p110δ nucleotide sequence:

```

1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
61 tattttcagg gcccatgga tccggaattc aaaggcctac gtcgacaaat gccccctggg
121 gtggactgcc ccatggagtt ctggaccaa gaggagagcc agagcgtggt tgttgacttc
181 ttgctgcccc caggggtcta cttgaacttc cccgtgtccc gcaatgcca cctcagcacc
241 atcaagcagg tctgtggca cctgtcacag tatgagccac tcttcacat gctcagtgac
301 cccgaggcct atgtgttcac ctgtgtgaac cagcggcgg agcagcagga gttggaggat
361 gagcagcggg gctgtgcga catccagccc ttcctgccc gctgtgcct cgtggcccga
421 gagggggacc gcgtgaagaa gctcattaac tcccagatca gcctcctcat tggcaaaggt
481 ctccatgagt ttgattccct gcgggaccgg gaagtaaacc acttccgcac taagatgctc
541 cagttttgtg aagaggctgc tgctaccgc cagcagctgg gctgggtgga atggctgcag
601 tacagcttc cctgcagct ggagccctca gcaaggggtt ggcgggcgg cttattgctg
661 gtcagcaacc gagccctgct ggtcaactg aagttcagg gcagtgagga gagcttcacc
721 ttccaggtat ccaccaagga catgccctg gcactgatgg cctgtgccct ccgaaaaaag
781 gccacagtgt tccggcagc tctgggtggag cagcctgagg aatatgccct gcaggtgaac
841 gggaggcacg aatacctcta cggcaactac ccgctctgcc actttcagta catctgcagc
901 tgcctacaca gcgggctgac ccctcatctg accatggtcc actcctctc catccttgct
961 atgcgggatg agcagagcaa tcctgcccc caagtacaga aaccacgtgc caaacctccc
1021 ccgatccctg ccaagaagcc ctctctgtg tccctgtggt ccctggaaca gccattctcc
1081 attgagctga tcgagggccg aaaagtgaat gctgacgagc ggatgaagct ggttgttcag
1141 gccgggctct tccatggcaa tgagatgctg tgcaagactg tgtcaagctc ggaggtgaat
1201 gtatgctcag agcccgtgtg gaagcagcga ctggagtctg atatcagcgt ctgtgacctc
1261 ccgcgcatgg ctgcactctg tttgtctctc tatgccctgc tggagaaggc taagaaggca
  
```

Certificate of Analysis

```
1321 cgctccacaa agaagaagtc taagaaggcg gactgcccc a tcgcttgggc caacctcatg
1381 ctattcgact acaaagatca gctcaagac ggggagcgct gcctctacat gtggccctct
1441 gtcccagatg agaagggaga gctgctgaat cctgcgggta cagtgcgagg gaacccaac
1501 acggagagtg ccgctgcct ggtcatctac ctgcctgagg tggccccc a ccctgtgtac
1561 ttccccgctc tggagaagat cctggagctg gggcgtcacg gggagcgtgg gcgcatcacg
1621 gaggaggagc agctgcagct gcgggagatc ctggaacggc ggggatccgg ggaactgtac
1681 gaacatgaga aggacctggt gtggaagatg cggcacgaag tccaggagca tttcccagag
1741 gcgctggccc gcctgctgct ggtcaccaag tggataaac acgaggatgt ggcccagatg
1801 ctctatattg tgtgctcctg gcccagctg cctgtgctga gcgccctgga acttctggac
1861 tttagctttc ccgactgcta cgtgggtccc ttgcctatca agtcccttcg gaagctgacg
1921 gacgatgagc tctccagta cttctgcag ctggtgcaag tgctcaaata tgagtcctac
1981 ctggactcgc agctgaccaa attctgctg ggccgagccc tggctaaccg caagatcgga
2041 cacttctgtg tctggcacct ccgctctgag atgcacgtac catcagtggc tctgcggttt
2101 ggtctcatca tggaaagccta ctgcagagc agcaccacc acatgaagggt gctgatgaag
2161 cagggggaag cactgagcaa gcttaaggca ctgaatgact ttgtgaagggt gagttcccag
2221 aagaccacca agcccaaac caaggagatg atgcatatgt gcatgcgcca ggagacctac
2281 atggaggccc tgtcccacct gcagtctcca ctgcaccaca gcaccctgct ggaggaagtc
2341 tgtgtggagc agtgcacctt catggactcc aaaatgaagc ccctgtggat catgtacagc
2401 agcaggaggc cgggcagtgc tggcaacgtg ggcatcatct ttaagaacgg ggatgacctc
2461 cgccaggaca tgctgactct gcagatgac cagctcatgg acgtcctgtg gaagcaggag
2521 ggccctggacc tgaggatgac gccctacggc tgcctccca ccggggaccg cacaggcttc
2581 atcagggtgg tcctccactc ggacaccatc gccaacatcc agctgaaca aagcaacatg
2641 gcggccacag ctgccttcaa caaggacgcc ctgctcaact ggctcaagtc caagaaccct
2701 ggggaggccc tggatcgggc cattgaggaa ttcaccctct cctgtgctgg ctactgtgtg
2761 gccacatatg ttctgggcat cgggtaccgg cacagcgaca acatcatgat cagagagagt
2821 gggcagctct tccacattga ttttggccac tttctgggga acttcaagac caagtttggg
2881 atcaaccgag agcgcgtccc cttcattctc acctacgact ttgtccacgt gatccagcag
2941 gggaaagacta acaacagtga gaagttttaa aggttccgcg gctactgtga acgagcctat
3001 accatcctgc ggcgccacgg gctgctttc ctccatctct tcgccctgat gcgggcccga
3061 ggtctgcctg agcttagctg ctccaaagat atccagtatc tcaaggactc tctggcactg
3121 gggaaagacgg aggaagaggc gctaaagcac ttccgggtga agttcaacga agctctccga
3181 gaaagctgga aaaccaaagt caactggctg gcgcacaatg tgtccaagga taaccgacag
3241 taa
```

Certificate of Analysis

p85α Sequence Information

<u>Protein</u>	Mouse p85α
<u>Tags</u>	Untagged
<u>Native sequence</u>	M1 of the recombinant protein is equivalent to M1 of mouse p85α
<u>Accession number</u>	GenBank NM_001077495

Recombinant p85α amino acid sequence:

```

1 MSAEGYQYRA LYDYKKEREE DIDLHLGDIL TVNKGSLVAL GFSDGQEARP EDIGWLNQYN
61 ETTGERGDFP GTYVEYIGRK RISPTPKPR PPRPLPVAPG SSKTEADTEQ QALPLPDLAE
121 QFAPPDVAPP LLIKLLEAIE KKGLECESTLY RTQSSSNPAE LRQLLDCDAA SVDLEMIDVH
181 VLADAFKRYL ADLPNPVIPV AVYNEMMSLA QELQSPEDCI QLLKKLIRLP NIPHQCWLTL
241 QYLLKHFFKL SQASSKNLLN ARVLSEIFSP VLFRFPAASS DNTEHLIKAI EILISTEWNE
301 RQPAPALPPK PPKPTTVANN SMNNSLQD AEWYWGDISR EEVNEKLRDT ADGTFLVRDA
361 STKMHGDYTL TLRKGGNKL IKIFHRDGKY GFSDP LTFNS VVELINHYRN ESLAQYNPKL
421 DVKLLYPVSK YQQDQVVKED NIEAVGKLLH EYNTQFQEK S REYDRLYEEY TRTSQEIQMK
481 RTAIEAFNET IKIFEEQCQT QERYSKEYIE KFKREGNEKE IQRIMHNHDK LKSRISEIID
541 SRRRLEEDLK KQAAEYREID KRMNSIKPDL IQLRKTRDQY LMWLTQKGVR QKKLNEWLGN
601 ENTEDQYSLV EDDELPHHD EKTWNVGS SN RNKAENLLRG KRDGTFLVRE SSKQGCYACS
661 VVVDGEVKHC VINKTATGYG FAEPYNYLSS LKELVLHYQH TSLVQHNSL NVTLAYPVYA
721 QRRR

```

Recombinant p85α nucleotide sequence:

```

1 atgagtgctg aggggtacca gtacagagca ctgtacgact acaagaagga gcgagaggaa
61 gacattgacc tacacctggg ggacatactg actgtgaata aaggctcctt agtggcactt
121 ggattcagtg atggccagga agccccgctt gaagatattg gctggttaaa tggctacaat
181 gaaaccactg gggagagggg agactttcca ggaacttacg ttgaatacat tggaaaggaaa
241 agaatttcac cccctactcc caagcctcgg cccccctgac cgcttcctgt tgctccgggt
301 tcttcaaaaa ctgaagctga cacggagcag caagcgttgc ccttcctga cctggccgag
361 cagtttgccc ctctgatgt tgccccgctt ctcttataa agctcctgga agccattgag
421 aagaaaggac tggaaatggt gactctatac agaacacaaa gctccagcaa cctgcagaa
481 ttacgacagc ttcttgattg tgatgcccgg tcagtggact tggagatgat cgacgtacac
541 gtcttagcag atgctttcaa acgctatctc gccgacttac caaatcctgt caticctgta
601 gctgtttaca atgagatgat gtctttagcc caagaactac agagccctga agactgcatc
661 cagctgttga agaagctcat tagattgcct aatatacctc atcagtgttg gcttacgctt
721 cagtatttgc tcaagcattt tttcaagctc tctcaagcct ccagcaaaaa ccttttgaat
781 gcaagagtcc tctctgagat tttcagcccc gtgcttttca gatttccagc cgccagctct
841 gataaactg aacacctcat aaaagcgata gagattttaa tctcaacgga atggaatgag
901 agacagccag caccagcact gcccccaaaa ccaccaagc ccactactgt agccaacaac
961 agcatgaaca acaatatgtc cttgcaggat gctgaatggg actgggggaga catctcaagg
1021 gaagaagtga atgaaaaact ccgagacact gctgatggga cctttttggg acgagacgca
1081 tctactaaaa tgcacggcga ttactactctt aactaagga aaggaggaaa taacaaatta
1141 atcaaaatct ttcaccgtga tggaaaatat ggcttctctg atccattaac cttcaactct
1201 gtggttgagt taataaacca ctaccggaat gactctttag ctcagtacaa cccaagctg
1261 gatgtgaagt tgctctacc agtgtccaaa taccagcagg atcaagttgt caaagaagat
1321 aatattgaag ctgtagggaa aaaattacat gaatataata ctcaatttca agaaaaaagt
1381 cggaatatg atagattata tgaggagtac acccgactt cccaggaaat ccaaatgaaa
1441 agaacggcta tcgaagcatt taatgaaacc ataaaaatat ttgaagaaca atgccaacc
1501 caggagcggg acagcaaaga atacatagag aagttaaacc gcgaaggcaa cgagaaagaa
1561 attcaagga ttatgcataa ccatgataag ctgaagtcgc gtatcagtga gatcattgac

```

Certificate of Analysis

```
1621 agtaggagga ggttgaaga agacttgaag aagcaggcag ctgagtaccg agagatcgac
1681 aaacgcatga acagtattaa gccggacctc atccagttga gaaagacaag agaccaatac
1741 ttgatgtggc tgacgcagaa aggtgtgcgg cagaagaagc tgaacgagtg gctggggaat
1801 gaaaataccg aagatcaata ctccctggta gaagatgatg aggatttgcc ccaccatgac
1861 gagaagacgt ggaatgtcgg aagcagcaac cgaaacaaag cggagaacct attgcgaggg
1921 aagcgagacg gcactttcct tgtccgggag agcagtaagc agggctgcta tgcctgctcc
1981 gtagtggtag acggcgaagt caagcattgc gtcattaaca agactgccac cggctatggc
2041 tttgccgagc cctacaacct gtacagctcc ctgaaggagc tggtgctaca ttatcaacac
2101 acctccctcg tgcagcacia tgactccctc aatgtcacac tagcataccc agtatatgca
2161 caacagaggc gataa
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services